BIOMAT Database Logo BIOMAT Database Logo

High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. 1996

M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Consecutive patients with non-Hodgkin's lymphoma (NHL, n = 133) or Hodgkin's disease (HD, n = 20) were treated with 12.0 Gy of fractionated total body irradiation, etoposide 60 mg/kg, and CY 100 mg/kg followed by infusion of autologous hematopoietic stem cells. Seventy-nine patients received purged (n = 62) or unpurged BM (n = 17), and 74 received unpurged PBSCs alone (n = 56) or with BM (n = 18). The median day for achieving a sustained granulocyte count of 0.5 x 10(9)/I was 14 range (7-66) for BM recipients and 10 (7-30) for PBSC +/- BM recipients (P = 0.03). A platelet count of 20 x 10(9)/I was achieved at a median of day 24 (6-145) in BM recipients and day 11 (range, 7-56) in PBSC +/- BM recipients (P = 0.007). The median number of platelet units transfused was 86 (0-1432) for BM recipients and 30 (6-786) for PBSC +/- BM recipients (P = 0.001). The median number of hospital days was 36 (10-88) for BM recipients and 27 (14-76) for PBSC +/- BM recipients (P = 0.0001). The unadjusted Kaplan-Meier (KM) estimates of survival, event-free survival (EFS) and relapse at 2 years were 0.57, 0.45 and 0.43 for patients receiving BM and 0.55, 0.36 and 0.59 for patients receiving PBSC +/- BM. After adjusting for confounding variables, the estimated relative risk (RR) of death from any cause was 0.92 (P = 0.75), of relapse was 1.25 (P = 0.39), of non-relapse mortality was 0.71 (P = 0.42) and of mortality and/or relapse was 1.17 (P = 0.48) for patients receiving PBSC +/- BM as compared to BM. For 46 patients with NHL receiving unpurged PBSC alone, the unadjusted KM estimate of relapse was 0.61 compared with 0.48 for 52 comparable patients receiving purged BM, while the RR for relapse for patients receiving unpurged PBSCs was 1.37 (P = 0.33) after adjusting for other significant covariates. These data confirm previous observations that patients who receive PBSC +/- BM have faster engraftment, fewer transfusions and shorter hospital stays than patients who receive only BM. There were no statistically significant differences between the two groups in survival, relapse, death from causes other than relapse and event-free survival.

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide

Related Publications

M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
High dose cyclophosphamide, fractionated total body irradiation with involved field irradiation and autologous bone marrow transplantation in malignant lymphoma.
January 1996, Leukemia & lymphoma,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas.
July 1991, Bone marrow transplantation,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma.
April 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
March 2000, Bone marrow transplantation,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
September 1992, American journal of hematology,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
July 1986, Cancer treatment reports,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.
June 1984, The New England journal of medicine,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
June 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
September 1989, Bone marrow transplantation,
M W Brunvand, and W I Bensinger, and E Soll, and C H Weaver, and S D Rowley, and F R Appelbaum, and K Lilleby, and R A Clift, and T A Gooley, and O W Press, and A Fefer, and R Storb, and J E Sanders, and P L Martin, and T Chauncey, and R T Maziarz, and N Zuckerman, and P Montgomery, and R Dorn, and P L Weiden, and T Demirer, and L A Holmberg, and K Schiffman, and P A McSweeney, and C D Buckner
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
September 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!